Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4299612
Max Phase: Preclinical
Molecular Formula: C76H103N23O17
Molecular Weight: 1610.80
Molecule Type: Unknown
Associated Items:
ID: ALA4299612
Max Phase: Preclinical
Molecular Formula: C76H103N23O17
Molecular Weight: 1610.80
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC[C@@H]1C(=O)NCC(=O)N1CCC[C@@H]1C(=O)NCC(=O)N1CCC[C@@H]1C(=O)NCC(=O)N1CCC[C@@H]1C(=O)NCC(=O)N1CCC[C@@H]1C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Standard InChI: InChI=1S/C76H103N23O17/c1-44(100)90-52(34-47-36-80-43-89-47)68(109)92-51(32-45-14-3-2-4-15-45)67(108)91-50(18-7-25-81-76(78)79)66(107)93-53(33-46-35-82-49-17-6-5-16-48(46)49)75(116)99-31-13-24-59(99)74(115)88-42-65(106)98-30-12-23-58(98)73(114)87-41-64(105)97-29-11-22-57(97)72(113)86-40-63(104)96-28-10-21-56(96)71(112)85-39-62(103)95-27-9-20-55(95)70(111)84-38-61(102)94-26-8-19-54(94)69(110)83-37-60(77)101/h2-6,14-17,35-36,43,50-59,82H,7-13,18-34,37-42H2,1H3,(H2,77,101)(H,80,89)(H,83,110)(H,84,111)(H,85,112)(H,86,113)(H,87,114)(H,88,115)(H,90,100)(H,91,108)(H,92,109)(H,93,107)(H4,78,79,81)/t50-,51+,52+,53+,54-,55+,56+,57+,58+,59+/m0/s1
Standard InChI Key: YTZSQMFKINJFMG-VDMXHDAPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1610.80 | Molecular Weight (Monoisotopic): 1609.7902 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Lensing CJ, Freeman KT, Schnell SM, Adank DN, Speth RC, Haskell-Luevano C.. (2016) An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers., 59 (7): [PMID:26959173] [10.1021/acs.jmedchem.5b01894] |
Source(1):